For non‐ACC salivary gland cancers (non‐ACC SGC), targeted therapy based on molecular markers (e.g., AR, HER2, and NTRK) is indicated in the absence of suitable clinical trials. Here, ERBB2 is linked to adrenal cortex carcinoma.